Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer
Acta Materia Medica · 2024 · 3 (2)
DOI: 10.15212/amm-2024-0015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Materia Medica, 2024. Verfasst von Yajun Chu und 6 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Elevated cellular oxidative stress is a common marker of cancer cell dysregulation caused by malignant transformation. Thioredoxin reductase (TrxR, encoded by TXNRD ) is a crucial enzyme that regulates cellular oxidative stress and the survival of many types of cancer cells. Therefore, targeting TrxR may lead to selective cell death in cancer cells. Pristimerin, a plant triterpenoid, increases the accumulation of reactive oxygen species (ROS) in cells, but its specific regulatory mechanism is unclear. Herein, we found that pristimerin selectively targets TrxR and subsequently induces apoptosis in human non-small cell lung cancer cells, and inhibits tumor growth in vivo with low toxicity to normal cells. Pristimerin was found to inhibit cancer cell growth primarily by inhibiting cellular TrxR, thereby compromising TrxR’s antioxidant function in cells and resulting in the accumulation of oxidized Trx. Furthermore, excessive ROS accumulation stimulated by pristimerin triggered tumor-specific amplification of oxidative stress in cancer cells and ultimately led to targeted destruction of cancer cells. Our data may support the development of potential therapeutic molecules as selective anticancer agents targeting highly enriched TrxR in cancer cells.
Zitieren
APA
Chu, Y., Xu, Q., Zhou, X., Nie, Q., Yao, X., Fang, J., & Zhang, J. (2024). Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer. Acta Materia Medica, 3(2). https://doi.org/10.15212/amm-2024-0015
Vancouver
Chu Y, Xu Q, Zhou X, Nie Q, Yao X, Fang J, et al. Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer. Acta Materia Medica. 2024;3(2). doi:10.15212/amm-2024-0015
BibTeX
@article{Chu2024,
author = {Chu, Yajun and Xu, Qianhe and Zhou, Xiedong and Nie, Qiuying and Yao, Xiaojun and Fang, Jianguo and Zhang, Junmin},
title = {Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer},
journal = {Acta Materia Medica},
year = {2024},
volume = {3},
number = {2},
doi = {10.15212/amm-2024-0015}
}
EUVIMED